MIBG Treatment for Neuroblastoma Now Available at Nationwide Childrens Hospital

May 20, 2014

Meta-iodobenzylguanidine (MIBG) therapy is now offered by Hematology/Oncology/Blood and Marrow Transplant at Nationwide Children’s Hospital. Patients with neuroblastoma who qualify for treatment with MIBG therapy can be treated in this new facility, with round-the-clock supervision by specially trained staff through video and audio monitoring.

Instead of the dark, basement rooms offered for this cancer treatment at many other institutions, the MIBG treatment suite at Nationwide Children’s boasts a view from the hospital’s 12th floor, complete with a private bathroom and connected parent room. Parents or guardians can monitor and communicate with their child through a glass partition and even help set up movies or television programs.

MIBG is a chemical that started as a blood pressure medicine. It was found to be preferentially picked up by neural crest cells which give rise to, among other things, parts of your adrenal glands. Neural crest cells can also give rise to a type of cancer, neuroblastoma. Neuroblastomas are in a class of tumors (called neuro-endocrine tumors) that will take up MIBG and can respond to treatment with MIBG.

The new MIBG room is double the size of standard patient rooms, and the attached parent suite includes a bed. Because patients undergoing this therapy may be treated in the MIBG room for up to five days, the facility was designed with patient and family comfort in mind.

More information on the MIBG treatment process including an animated tour of the room and a photo gallery can be viewed at nationwidechildrens.org/mibg-room.

About Nationwide Children's Hospital

Named to the Top 10 Honor Roll on U.S. News & World Report’s 2024-25 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit free-standing pediatric health care systems providing unique expertise in pediatric population health, behavioral health, genomics and health equity as the next frontiers in pediatric medicine, leading to best outcomes for the health of the whole child. Integrated clinical and research programs, as well as prioritizing quality and safety, are part of what allows Nationwide Children’s to advance its unique model of care. Nationwide Children’s has a staff of more than 16,000 that provides state-of-the-art wellness, preventive and rehabilitative care and diagnostic treatment during more than 1.8 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities. More information is available at NationwideChildrens.org